LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Neurocrine Biosciences Inc

Fechado

SetorSaúde

125.37 0.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

123.7

Máximo

125.71

Indicadores-chave

By Trading Economics

Rendimento

-95M

7.9M

Vendas

-55M

573M

P/E

Médio do Setor

42.224

51.198

EPS

0.7

Margem de lucro

1.38

Funcionários

1,800

EBITDA

-146M

24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+28.6% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

698M

12B

Abertura anterior

124.57

Fecho anterior

125.37

Sentimento de Notícias

By Acuity

50%

50%

166 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Neurocrine Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jan. de 2025, 00:03 UTC

Ações em Alta

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13 de ago. de 2024, 11:30 UTC

Principais Notícias

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Comparação entre Pares

Variação de preço

Neurocrine Biosciences Inc Previsão

Preço-alvo

By TipRanks

28.6% parte superior

Previsão para 12 meses

Média 160.25 USD  28.6%

Máximo 192 USD

Mínimo 115 USD

Com base em 21 analistas de Wall Street que oferecem metas de preço de 12 meses para Neurocrine Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

21 ratings

19

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

109.55 / 121.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

166 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.